Internal medicine

Pathology

Clinical endpoint

Hazard ratio

Placebo

Empagliflozin

Canagliflozin

Heart failure

Diabetes mellitus

Endocrinology

Cardiology

Alternative medicine

Type 2 diabetes

Dapagliflozin

Type 2 Diabetes Mellitus

Confidence interval

Clinical trial

Medicine

Circulation

Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces the risk of cardiovascular events. We report the effects on heart failure (HF) and cardiovascular death overall, in those with and without a baseline history of HF, and in other participant subgroups.

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus